Hung Luu

Children’s

Riki Merrick

Vernetzt, APHL

Andrea Pitkus

UW

Pam Banning

3M - Solventum

Xavier Gansel

Biomerieux

Amy McCormick

Epic

Dan Rutz

Epic

Rob Rae

CAP

Rob Hausam

Hausam Consulting

Sandy Jones

CDC

Stan Huff

Graphite

Ed Heierman

Abbott / IICC

Andrew Quinn

Laurent Lardin

Biomerieux

Anthony Killeen

UMN

Craig Collom

Marti Velezis

 Sonrisa / FDA

Walter Sujansky

FDA

Susan Downer

JMC

Ralf Herzog

Roche

Cornelia Felder

Roche

Daniel Golson

JMC

Andrea Prada

JMC

Maria Sagat

 CAP

Raja Cholan

FDA

Russ Ott

FDA

Akila Namasivayam

FDA

Desiree Mustaquim

CDC

John Spinosa

Lantana

Reviewing minutes from the last call - Action Item Follow up

• Pull out the definitions from LIVD for test kit and equipment and put here: SHIELD Glossary

  • Review operational definition of “equivalence”

• Outreach to Dr. DeBaca

  • Hung will check for more info and maybe see, if she could participate in SHIELD

• Keep updating the googlesheet: Potassium LIVD data

• Shared Reportable Conditions LIVD google sheet for crowdsourcing with CSTE - added sign up sheet for PHAs to specific conditions and see how that develops

• Have LIVD File Repository Requirements

  Have draft budget (for setting up a web-based database and yearly maintenance): https://aphlinformatics.atlassian.net/wiki/download/attachments/915407143/LIDR - Budget.xlsx?api=v2

• Review LIDR Use Cases and sign up to lead one of these - prioritize these use cases, so that we can finalize the requirements for the first phase of LIDR

• Define next steps to migrate existing LIVD files into FHIR LIVD catalog format and find a FHIR server to host

• Riki to see, if Marti can share the LIDR categorical data to instance data mapping for each element

Call Schedule

send OOO via chat or email

LIDR Elements Discussion

 Not today

Review LIDR White Paper

Discussing the TINKAR work - we need to make sure all understand the differences between LIDR, lab compendiums and instance data

Reviewing the comments in the LIDR paper:

Raja added a sentence - Xavier to review to see, if that reolves his comments

DIscussion about the LOINC model statement - the LOINC model, like no other terminology currently can represent the same tests the same way - due to mapping interpretations and also to the level of granualrity that the LOINC model can accommodate - use ideally or initially designed

Attributes not provided by the IVD vendors in LIVD - like calculations or challenge test information - this may need to be curated by the LIDR team - add more examples to the section

Will start with “Roadmap for LIDR - Riki” review next week - goal of this section is to take the requirements Stan wrote up and put them in temporal order to create something useful right away and then expand on that

Also need to populate the “How to get involved” section - RIki wil l draft a few sentences - don't think it needs to be more than that.

ACTION ITEMS

Please see the action items at top of this page - Next deliverable is White paper draft by end of this month

Next call

Monday 4/8/2024 9 - 10 AM ET

Adjourned

 9:55 AM ET